Research Alert: CFRA Retains Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc.
I'm PortAI, I can summarize articles.
CFRA has retained a Hold opinion on Alnylam Pharmaceuticals, reducing its target price from $470 to $422 based on NPV analysis. The 2025 EPS forecast remains at $4.98, with a slight decrease in the full-year 2025 revenue estimate to $3.8B. The TTR franchise revenue is now projected at $2.49B. A recent $250M manufacturing investment aims to enhance capacity and reduce costs, positioning Alnylam as an innovation hub. Since the rating change to Hold on October 29, shares have declined over 17%.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments